BACKGROUND: Conditional survival estimates account for time survived since diagnosis to provide prognostic information for long-term cancer survivors. for rectal cancer, stage-related treatment (eg, neoadjuvant radiotherapy) affects pathologic stage and therefore stage-associated survival estimates.
C olorectal adenocarcinoma is the third most common cancer, with 143,460 new cases projected in 2012. 1 Rectal cancer cases represent approximately one third of these cases. survival after rectal cancer diagnosis and treatment depends on the stage of disease at presentation. overall, 5-year survival estimates range from 90% for stage i cancers to 7% for stage iV cancers. however, these traditional survival estimates made at the time of diagnosis of rectal cancer may be less meaningful for long-term survivors. it is becoming increasingly appreciated that, for patients who survive for some duration after their diagnosis, survival probabilities change over time. Conditional survival (Cs) takes into account the time survived since diagnosis and treatment in predicting future survival. Conditional survival may give more accurate survival estimates for patients with cancer, in particular, for those with advanced disease, and can give clinically relevant information upon which to base future treatment and surveillance. for example, a patient who has survived 3 years from initial diagnosis for rectal cancer may now have a different 5-year survival than initially predicted at diagnosis. the adjusted 5-year survival can be recalculated based on the time already survived and additional patient and tumor factors. this adjusted survival estimate can help patients make important life decisions and decrease uncertainty about their future.
the availability of large, population-based tumor registry data has facilitated such analyses, which have thus been reported for several cancer sites. [2] [3] [4] [5] [6] [7] [8] [9] [10] the technique for estimating Cs has recently been refined to incorporate covariate adjustment, 2 and, to facilitate access to this information by clinicians, internet-based tools for determining covariate-adjusted Cs estimates are now available for selected cancer sites including gallbladder, 11 melanoma, 12 and colon. 2 in a previous study among patients who have rectal cancer, Cs estimates were shown to improve over time. 9 however, the estimation of Cs among patients with rectal cancer is complicated by the need for perioperative multidisciplinary treatment, a factor not previously considered.
although surgical resection is the primary treatment for localized rectal cancer, radiation therapy (XRt), either given preoperatively or postoperatively, and generally with concurrent fluorouracil-based chemotherapy, improves locoregional control. [13] [14] [15] [16] Preoperative treatment of rectal cancer can influence final pathologic stage. for example, both tumor size and nodal status can be affected by preoperative XRt. therefore, survival estimates based on pathologic stage information must take in to account the sequence of XRt and surgical treatment. 17, 18 the objective of this study was to determine Cs estimates for patients who have rectal cancer by using a population-based cancer registry data set.
METHODS

Data Source and Case Identification
Data were retrieved from the surveillance epidemiology and end Results (seeR 17) Program, release 2010. 19 seeR collects cancer incidence and survival data from 18 regional population-based registries now covering approximately 26% of the us population. During most of the study inclusion period (through 2000), seeR captured incident data from approximately 14% of the us population. the seeR registries routinely collect data on patient demographics, primary tumor site, tumor morphology, pathologic stage at diagnosis, first course of treatment (radiotherapy and surgery), and patient follow-up for vital status. seeR does not collect data on chemotherapy, which was therefore not evaluated in this study.
Patients eligible for this study included those with adenocarcinoma of the rectum (International Classification of Diseases for Oncology, 3rd Edition codes 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8520-8551, 8560, 8570-8574, 8576, 8940-8941) who were diagnosed from January 1988 through December 2002. The inclusive study dates were chosen because 1988 was the first year seeR coded data elements that would allow restaging with the use of the American Joint Committee on Cancer sixth edition staging manual (AJCC 6th edition), 20 and 2002 was the last year of diagnosis with at least 5 years of follow-up. Based on available tnm data elements from pathologic staging, AJCC 6th edition stage assignment was determined for each case. exclusion criteria included age younger than 18 or older than 90 years, in situ disease, lack of histologic confirmation or survival time information, and if incomplete data precluded AJCC 6th edition stage assignment. Patients were also excluded if the cancer-reporting source was a nursing home, hospice, autopsy, or death certificate, because these patients would not have been likely to receive cancer-directed therapy, or if death occurred within 30 days of diagnosis. additionally, patients were excluded if the incident diagnosis of rectal cancer was not their first and only occurrence of malignant disease.
Statistical Analysis
Cancer-specific survival (Css) was determined by using seeR data through December 2007; cases were censored if death was from a cause other than colorectal cancer or if the patient was alive at follow-up. Cancer-specific survival was estimated by using the Kaplan-Meier method. The multiplicative law of probability was used to calculate the Cs among patients with a minimum of 5 years of followup as previously described. 7 specifically, Cs represents the probability that a patient with cancer will survive an additional x years, given that the patient has already survived a given number of years (y). for example, to compute the x-year Cs for patients who have survived y years, the (x + y)-year Css is divided by the y-year Css, thus yielding cancer-specific Cs.
to account for the simultaneous effect of multiple variables on survival, including factors associated with secular trends in preoperative vs postoperative XRt, separate multivariate Cox regression models were built for patients who underwent no XRt, preoperative XRt, postoperative XRt, or had stage iV disease. separate models were used to account for potential imbalance in the different treatment groups based on selection bias for adjuvant therapy or pathologic tumor downstaging associated with preoperative radiotherapy. however, the covariates adjusted in the model were the same for the 3 models for patients with localized stage (stage i-iii), including age (<50, 50-59, 60-69, 70-79, 80+), sex (male, female), race (white, black, other), tumor grade (low (well differentiated, moderately differentiated), high (poorly differentiated or undifferentiated), or unknown), surgery type (local excision and radical surgery) and AJCC 6th edition stage. A fourth model was used for patients with distant metastasis for which the use of any radiotherapy or primary tumordirected surgery were included as binary covariates in the model. adjusted survival estimates were calculated at years 1 through 10 by category of age, sex, race, tumor grade, and stage, and these estimates formed the basis to generate 5-year adjusted Cs for patients who had survived 1 through 5 years. the proportional hazards assumption was verified graphically on the basis of schoenfeld residuals. 21 the 4 final models were used to develop an internet browser-based Cs calculator to predict individualized Css and Cs. model performance was internally validated by calibration that was graphically evaluated by the goodness-of-fit test for Cox regression by using the stcoxgof module for stata. 22 the plot presents the observed and model-predicted expected risk of cancer-specific death in each decile of risk. statistical analyses were performed by using stata mP Version 10.0 (release 2007, College station, tX). Because the study used preexisting data with no personal identifiers, this study was exempt from review by our institutional review board.
RESULTS
the clinicopathologic characteristics of the 22,610 patients are shown in table 1. the majority of patients were white men between the ages of 60 and 79 who had lowgrade tumors (well or moderately differentiated). Patients with stage i and ii disease represented 48% of the cohort, 30.4% had stage iii disease, and 21.7% had stage iV disease. Radical surgery, consisting of resection of the rectum by either low anterior resection or abdominoperineal resection, was performed in 87.9%. the majority of patients (57.4%) received no radiation (XRt). Radiation therapy was given preoperatively to 14.1% of patients and postoperatively to 28.4%.
Traditional and Crude CS Estimates
The traditional 10-year CSS by AJCC stage is shown in figure 1 . the entire cohort was followed for at least 5 years after diagnosis or until death. the median followup time was 89 months. the final model used for the adjusted analyses is shown in table 2. the calibration plot indicated good agreement between the model-predicted and observed risk of cancer-specific death in each decile of risk, as shown in figure 2 . the 5-year crude Cs by stage is shown in figure 3 and was noted to increase over 5 years among all stages. the change in Cs over 5 years was least pronounced in patients who had stage i disease who have a high survival probability at diagnosis (90% 5-year Cs at diagnosis vs 92% at 5 years from diagnosis). the most significant improvements in Cs were observed in patients with advanced-stage disease. Conditional survival estimates increased from 42% at the time of diagnosis to 75% at 5 years, and from 7% to 61% at 5 years for patients with stage iiiC and iV disease.
Adjusted CS Estimates Stratified by Sequence of XRT
in order to evaluate the impact of patient, tumor, and treatment factors on Cs estimates, survival models adjusted for age, sex, ethnicity, tumor grade, and AJCC stage were constructed and stratified into no XRt, preoperative XRt, postoperative XRt, or stage iV disease. the adjusted Cs estimates at year 0, year 5, and the absolute survival improvement at 5 years for the stratified models are shown in table 2. Patients who were older, who were black, and who had higher grade tumors experienced the greatest improvements in Cs at 5 years in comparison with their counterparts, and the effects were most pronounced in patients receiving XRt, pre-or postoperatively. as observed in the crude (unadjusted) Cs model, the adjusted Cs estimates improved over time for all stages and across all 3 XRt-stratified groups, with the greatest absolute survival improvements observed in patients with stage iiiC disease receiving preoperative XRt and stage iV disease (27.8% and 44.9% improvement in survival at 5 years).
Adjusted CS Estimates Stratified by
Stage the adjusted Cs model revealed additional associations between stage of disease and XRt ( fig. 4 ). for example, patients with stage i disease receiving postoperative XRt had a worse initial survival in comparison with no XRt or preoperative XRt ( fig. 4a ). Patients with stage iiiB and iiiC disease receiving preoperative XRt had worse initial survival in comparison with postoperative XRt ( fig. 4e  and 4f ). the no XRt group had lower Cs rates over time in comparison with pre-and postoperative XRt groups. however, these differences decreased over time.
Cox Regression Models for Adjusted CSS
separate Cox regression models were used to retrieve adjusted Css estimates for 4 groups of patients: no XRt therapy, preoperative XRt, postoperative XRt, and stage iV disease (table 3) . age ≥60 was a significant adverse prognostic factor in patients receiving no XRt or preoperative XRt and for patients with stage iV disease; age ≥50 was a significant adverse prognostic factor for patients in the postoperative XRt group. Black ethnicity, high tumor grade, and AJCC stage were significant adverse prognostic factors among all 3 groups. lack of surgical resection was an adverse predictor among patients with stage iV disease (hR, 1.66; 95% Ci, 1.38-1.99) likely reflecting a selection bias for lower disease burden in the cohort of patients with metastatic disease undergoing primary resection. the internet-based Cs calculator is available at www.mdanderson.org/rectalcalculator.
DISCUSSION
in this population-based study of 22,610 patients with rectal adenocarcinoma, we examined covariate-adjusted Cs probabilities stratified by treatment sequence and pathologic stage. We identified improvements in 5-year Cs among all stages during the follow-up period after initial diagnosis, with the greatest increases in patients with more advanced stage. We also observed that the use and timing of XRt affected Cs estimates because of the effects of preoperative therapy on final pathologic stage. in addition, patients who were older, who were black, or who had higher-grade tumors all had lower initial survival estimates, but also experienced greater improvements in survival in comparison with their counterparts, especially among the preoperative XRt group. using these data, we developed a unique, interactive Web-based calculator to provide individualized decision support for use in counseling patients during the survivorship period. traditional survival estimates, which are determined at the time of diagnosis or treatment, may lose meaning 
The over time. studies of Cs provide valuable information to patients and their treating physicians by taking into account the time previously survived in predicting future survival and providing a more clinically relevant estimate of survival for cancer survivors. Conditional survival estimates have been determined for several types of cancer, including colon and rectal cancer, but there are additional considerations related to the use of perioperative radiotherapy for determining Cs for rectal cancer. in an analysis of the seeR registry with more than 83,000 patients, we demonstrated time-dependent gains in Cs for patients with colon cancer; and, in the present analysis, similar observations were noted for patients with rectal cancer. 2 there are a number of issues in cancer survivorship that are related to the expectation of future survival, and fear of recurrence can be the single largest concern among patients and their caregivers. [23] [24] [25] [26] especially among patients with advanced stage disease, knowledge regarding improvements in Cs over time can reduce anxiety and improve quality of life.
a unique feature of our study is the use of covariateadjusted analysis as well as the development of separate treatment-stratified adjusted regression models to account for the potential unmeasured effects associated with differences in the use and timing of radiotherapy. Perioperative XRt, most commonly given in combination with fluorouracil-based chemotherapy in the united states, plays a key role in the treatment of locally advanced rectal cancer. 15, 27, 28 Preoperative XRt results in pathologic tumor regression with a decrease in tumor size, depth of penetration, and nodal stage, which can affect stage at registration and influence stage-dependent outcomes. 17, 27, [29] [30] [31] [32] Patients with node-positive disease receiving no XRt had the worst initial stage-specific survival in comparison with patients in the no XRt or postoperative XRt groups, with the largest differences observed among patients with stage iiiC disease, for whom the 5-year survival at the time of diagnosis was 43.5%, 36.2%, and 47.5% for preoperative XRt, no XRt, and postoperative XRt. however, these survival differences decreased over time and, in fact, reversed in favor of the preoperatively treated patients. at 5 years, patients receiving preoperative XRt had the greatest absolute improvements in Cs, analogous to the effects observed for patients with stage iV disease. interestingly, among patients with stage iiB (t4) disease, the effect of preoperative radiotherapy on improving survival also translated to a persistently improved Cs probability as shown in figure 4C . although the impact of preoperative radiotherapy for rectal cancer on survival is a subject of a trans-atlantic controversy, our results suggest that a permanent survival benefit may exist in the stage iiB subcohort. 14,33 thus, the declining risk for cancer mortality over time can be individually quantified by using our analysis.
it is also important to consider patients who had not undergone pelvic radiotherapy separately, because this group is subject to treatment bias, particularly among those patients with stage ii or iii cancers whose long-term outcomes might have been affected by the use of adjuvant therapy. We also separately modeled Cs among patients with stage iV disease, because these patients represent a different patient population than those with resected localized disease and for whom the regression models for localized disease cannot be applied.
thus, our use of separate regression models stratified by the use and timing of radiotherapy or the presence of stage iV disease accounts for these unmeasured treatment-related effects as demonstrated by the calibration plot. to facilitate the use of this information in daily clinical practice, we have developed an interactive Webbased tool for calculating Cs that adjusts not only for the covariate effects, but also for treatment and outcome differences associated with the stratified treatment groups (www.mdanderson.org/rectalcalculator). the calculator is a decision-support tool personalized to the patient, tumor, and treatment course. in contrast to the traditional 5-year survival estimates in which predictions are made for diverse groups of patients based on stage alone, the Cs calculator can give individualized future survival estimates that also account for patient-related factors such as age and race, which have also been shown to be independently associated with traditional survival estimates. 34, 35 our study has both strengths and limitations inherent to the data source. Data on chemotherapy treatment is not available in seeR, and, therefore, the impact of this treatment on Cs estimates cannot be accounted for in the present analysis. however, most patients who undergo radiotherapy for rectal cancer in the united states undergo combined-modality chemoradiotherapy, both preoperatively and postoperatively, based on multi-institutional randomized data. 15, 27, 36, 37 seeR also does not include data on medical comorbidities or postoperative complications that may impact survival estimates; however, we have used Css estimates and have additionally confirmed our findings by using relative survival. furthermore, we have excluded cases with death within 30 days to minimize the confounding effect of early postoperative mortality. there are also limitations in seeR staging information for patients who have received neoadjuvant therapy, because seeR staging does not distinguish between clinical and pathologic stage. therefore, patients who achieve a pathologic complete response after neoadjuvant chemoradiotherapy may be coded in seeR as unknown t or n stage, representing a small cohort of patients whose evaluation is uniquely limited in seeR. Because seeR does not have a classifier for pathologic complete response following neoadjuvant chemoradiotherapy, many of these patients will be classified as unstaged (because of the lack of an available viable tumor), and, therefore, our calculator cannot be applied to these patients. however, these patients have been shown to have excellent prognosis that is better than that of patients with residual stage i disease. 18, 38 it should also be noted that the Cs estimates are based on patients alive at each time point without information regarding disease status (ie, alive with or without evidence of disease); thus, for individuals whose disease status is known, a small variance of the actual Cs from the Cs estimates can be expected. finally, because advances in effective systemic treatment regimens have improved survival outcomes in recent years, our analysis may potentially underestimate the survival outcomes, particularly for patients with localized disease.
CONCLUSIONS
We report on covariate adjusted, treatment-stratified, Cs outcomes among patients with rectal cancer and have created an internet-based electronic tool for real-time information to estimate Cs and facilitate patient counseling. in so doing, we have accounted for variations in outcome that are related to initial treatment decisions. these estimates may be useful to clinicians in counseling patients on prognosis and in planning future treatment and intensity of surveillance for rectal cancer survivors. 
